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Pharmacokinetics of Ertapenem in Sheep (Ovis aries) with Experimentally 
Induced Urinary Tract Infection 
Abstract 
Sheep are commonly used as animal models for human biomedical research, but descriptions of their use 
for studying the pharmacokinetics of carbapenem antimicrobials, such as ertapenem, are unavailable. 
Ertapenem is a critical antimicrobial for human infections, and the description of the pharmacokinetics of 
this drug is of value for research using ovine as models for human diseases, such as urinary tract 
infections (UTI). There are currently no ovine models for comparative biomedical research of UTI. The 
objective of this study was to report the pharmacokinetics of ertapenem in sheep after single and 
multiple dosing. In addition, we explored the effects of an immunomodulatory drug (Zelnate) on the 
pharmacokinetics of ertapenem in sheep. Eight healthy ewes (weight, 64.4 ± 7.7 kg) were used in an ovine 
bacterial cystitis model of human cystitis with Pseudomonas aeruginosa. After disease confirmation, 
each ewe received 1 g of ertapenem intravenously once every 24 h for 5 administrations. Blood was 
collected intensively (14 samples) during 24 h after the first and last administration. After multiple-dose 
administration, the volume of distribution was 84.5 mL/kg, clearance was 116.3 mL/h/kg, T1/2(λz) was 
1.1 h, and the extraction ratio was 0.02. No significant differences in pharmacokinetic parameters or time 
points were found between groups treated with the immunostimulant and controls or after the 1st or 5th 
administration of ertapenem. No accumulation was noted from previous administration. Our ovine 
pharmacokinetic findings can be used to evaluate therapeutic strategies for ertapenem use (varying drug 
dosing schedules and combinations with other antimicrobials or immune modulators) in the context of 
UTI. 
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Ertapenem is a member of the carbapenem family and as such 
has activity against gram-positive and gram-negative aerobic as 
well as anaerobic bacteria. This drug demonstrates bactericidal 
characteristics through binding to penicillin-binding proteins, 
thereby inhibiting bacterial cell wall synthesis. Due to its high 
degree of protein binding and stability against renal dehydro-
peptidase enzymes, ertapenem can be dosed once daily in hu-
mans.13 Similar among carbapenem antimicrobials, ertapenem 
demonstrates a postantibiotic effect, where bacterial growth is 
suppressed after concentrations fall below the minimal inhibi-
tory concentration of the organism.12 These characteristics allow 
for favorable use of ertapenem for the treatment of complicated 
urinary tract infections (UTI) in people, often with excellent 
efficacy.30,33
UTI are a leading cause of nosocomial and resistant bacte-
rial infections in human healthcare. New approaches to treat 
infection and models could be beneficial to develop treatment 
strategies and combat the high rate of resistance to infection. 
Complicated UTI are often associated with immunosuppres-
sion, renal disease, renal transplantation, or physical objects, 
such as urinary calculi and indwelling urinary catheters.19 Ani-
mal models of infection are critical for these types of studies, 
but traditional models, such as mice, do not work well for all as-
pects of urinary tract diseases, most notably due to size and the 
inability to place human urinary catheters. In addition, sample 
collection could be impaired in a murine model of cystitis due 
to indwelling catheterization, because only a limited volume of 
urine would be produced, and traditional methods of sample 
collection, such as cystocentesis, could induce artifact in the 
form of transient hematuria, which would be suboptimal for a 
longer-term study.8 Sheep research models are used for many 
human diseases including respiratory disease, hemophilia, and 
polycystic kidney disease.4,11,15 Sheep possess many attributes 
that are advantageous for research models, including body size, 
laboratory disposition, low cost, and longevity, and they can 
be catheterized for long periods of time, thus allowing for the 
collection of large volumes of urine. We do not advocate the 
treatment of ovine patients with carbapenem antibiotics but do 
recognize that—because of their attributes—sheep may serve as 
a model of infectious urinary tract disease for human biomedi-
cal research.
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Although ertapenem is used in human medicine for com-
munity-acquired pneumonia as well as mixed and complicated 
UTI, there are no reports of its use among veterinary species for 
human biomedical research.13 Drug efficacy is inherently related 
to drug exposure for carbapenem antibiotics, because time-de-
pendent exposure exceeding the MIC for 40% and 20% of the 
dosage interval is necessary to achieve a bactericidal or bacte-
riostatic effect.6 Therefore the development of a sheep model 
for testing various ertapenem dosing schedules or combination 
therapies will rely heavily on the comparative pharmacokinet-
ics of ertapenem. One of the primary steps in developing an 
animal model for human disease that requires ertapenem for 
treatment is a description of the pharmacokinetics of this drug 
in sheep (Ovis aries). The purpose of this study was to define the 
pharmacokinetics of ertapenem after single and multiple dosing 
in sheep undergoing experimental complicated catheter-associ-
ated cystitis with and without the use of an immunomodulator.
Materials and Methods
Experimental animals. All aspects of this project were 
reviewed and approved by the Iowa State University IACUC 
(log no. 3-15-7965-O). Eight ewes (weight, 64.4 ± 7.7 kg) were 
sourced from a commercial breeder and used for this study. 
Ewes were housed in a climate- and humidity-controlled room 
for the entirety of the study, with the first 72 h used for accli-
mation prior to initiation of the study. Animals were randomly 
assigned by body weight to 1 of 2 groups, an ertapenem-only 
group (n = 4) and an ertapenem-and-immunomodulator (Zel-
nate [ZN], Bayer HealthCare, Animal Health, Shawnee Mission, 
KS) group (n = 4). The ewes were housed in individual pens 
since arrival, and the study took place in the same individual 
pens for each ewe. After acclimation, no alterations to feeding 
or handling were made for this study. During the prestudy time 
period, all ewes were trained to be restrained by a halter placed 
on the head and tied to the wall of the pen. Criteria for enroll-
ment in this study included a normal physical exam that yielded 
vital signs within the normal limits of an adult ewe, no previ-
ous history of medical illness as well as no recent history of a 
previously administered medication. Both before and during 
the study, all sheep were fed a diet that either met or exceeded 
the National Research Council requirements for maintenance 
of ewes.
At 24 h prior to initiation of the study, ewes were restrained, 
and the skin of the neck was aseptically prepared by using 4 
alternating scrubs of chlorhexidine surgical scrub and 70% iso-
propyl alcohol. Prior to catheter placement, the skin at the cathe-
ter site was infiltrated with 2% lidocaine, and a 14-gauge, 5.5-in. 
catheter (MILACATH, MILA International, Florence, KY) were 
aseptically placed in each jugular vein. After catheter placement, 
an injection port was added, and the catheters were sutured to 
the skin and wrapped for security.
UTI was induced as described previously.24 After an acclima-
tion period, a Foley catheter was placed aseptically, the bulb 
was inflated with sterile saline, and ewes were inoculated with 
Pseudomonas aeruginosa strain ATCC 15442. The catheter was 
clamped for 4 h during the inoculation procedure and then left 
unclamped. Blood collection for the study began 72 h after in-
oculation.
Experimental design and sample collection. At 24 h prior to 
collection of samples, ewes in the immunomodulator group 
received 2.0 mL SC of ZN, a STING pathway activator;7 control 
ewes received a similar volume of 0.9% saline administered via 
the same route. At time 0, 1 gof ertapenem (Invanz, Merck, NJ) 
was given as a 60-s bolus through the jugular catheter designated 
for drug administration; blood was collected through the other 
jugular catheter, with predosing samples collected before drug 
administration and then at times 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 
10, 12, 24, 48, 72, and 96 h after drug administration. Ertapenem 
was administered at a dose of 1g every 24 h for 5 doses. At 96 
h, the fifth intravenous dose of ertapenem was given, and ad-
ditional samples were collected at 96, 96.25, 96.5, 96.75, 97, 97.5, 
98, 99, 100, 102, 104, 106, 108, and 120 h to describe pharmaco-
kinetics at presumed steady state, defined according to human 
pharmacokinetic data.2,9,13
At each sampling time point, blood was collected from the 
catheter by using a 12-mL syringe and placed into sodium hepa-
rin–treated tubes (Vacuum phlebotomy tube, Becton Dickinson, 
Franklin Lakes, NJ) The samples were then centrifuged at 1500 × 
g for 10 min. The plasma was collected, transferred to cryovials, 
and then stored at −80 °C until analysis.
Sample analysis. Standards were made in 0.1mM 2-[N-mor-
pholino]ethanesulfonic acid (MES) buffer containing 0.24M 
sodium fluoride at pH 6.5, refrigerated, and used within 3 d 
to ensure the stability of ertapenem.16,21 Frozen samples were 
thawed in cold water, vortexed, pipetted, and immediately re-
turned to –80 °C freezer to minimize degradation of ertapenem.
Analytical standards for plasma were prepared in 200 µL of 
blank ovine plasma at ertapenem concentrations of 0.25, 0.5, 1, 
2, 5, 10, 20, 50, 100, 200 µg/mL. Quality control samples were 
prepared in 200 µL blank ovine plasma at ertapenem concentra-
tions of 1.5, 30, and 150 µg/mL. Standards and quality controls 
were kept on ice when not in use. A 25-µg/mL solution of the 
internal standard, ertapenem-d4, was made in 0.1 mM MES 
buffer containing 0.24 M sodium fluoride at pH 6.5, and 10 µL 
was added to standards, quality controls, blank plasma, and 
samples.
We modified a previously published method for plasma sam-
ple preparation.20 For the standards, quality controls, blank and 
samples, an aliquot of 200 µL of plasma was transferred into a 
microfuge tube, and 0.25 µg ertapenem-d4 internal standard 
was added to each tube. A 200-µL portion of chilled 0.1 mM 
MES buffer, containing 0.24 M sodium fluoride, was added to 
each sample, followed by 600 µL of chilled acetonitrile. Samples 
were mixed by using a vortex mixer and then centrifuged for 
5 min at 2700 × g. The supernatant was decanted into another 
tube, to which was added 600 µL of chilled dichloromethane; 
the tube then was mixed by using a vortex mixer and centri-
fuged for 5 min at 2700 × g. A 100-µL portion of the top layer 
was transferred into a microvial containing a glass insert. Sam-
ples were then centrifuged for 20 min at 1500 × g in a chilled 
centrifuge. Standards and samples were kept on ice during the 
extraction procedure. Data points with concentrations above 
the range of the standard curve were diluted with blank plasma 
and reextracted to achieve a concentration within the range on 
the curve.
Ovine plasma concentrations of ertapenem were determined 
by using LC–MS/MS. A TSQ Quantum Discovery Max triple 
quadrupole was coupled to a Surveyor Pump with a chilled Au-
tosampler. (Thermo Scientific, San Jose, CA). The mobile phases 
consisted of (A) 0.1% formic acid in water and (B) 0.1% formic 
acid in acetonitrile. The mobile phase began at 15% B with a 
linear gradient to 70% B at 2.5 min, followed by reequilibration 
to 15% B. A Kinetex phenyl hexyl column was used (100 mm 
× 2.1 mm, 2.6-µm particles) from Phenomenex (Torrance, CA) 
with the column temperature set to 35 °C. The injection volumes 
were 10 µL for plasma and 2 µL for urine. The following ions 
were used for identification: ertapenem (m/z 476) 68, 114, and 
432 and ertapenem-d4 (m/z 480) 68, 114, and 436. The retention 
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time for both compounds was 1.8 min. The 432 and 436 ions 
were used for quantitation of ertapenem and ertapenem-d4, 
respectively.
Calibration curves were calculated by using the Quan 
Browser module of Xcalibur software (Thermo Scientific, San 
Jose, CA) and quadratic fit. All correlation coefficients (R2) ex-
ceeded that of 0.99. The calibrators were within a tolerance of 
15% of the nominal value, except for the lower limit of quantita-
tion, which was less than 20%. The quality controls were within 
a tolerance of ±15% of the nominal value. The limit of detection 
(LOD) was 0.1 µg/mL for ovine plasma. The limit of quantita-
tion, which was based on the calibration curve, was 0.25 µg/mL 
for ovine plasma.
Pharmacokinetic analysis. Pharmacokinetic analysis of to-
tal ertapenem plasma concentration was completed using a 
noncompartmental module in commercial software (Phoenix 
WinNonlin 8.0, Certara, Princeton, NJ). Figures showing time 
plotted against concentration of ertapenem were produced by 
using a commercial program (Prism 8, GraphPad Software, La 
Jolla, CA). (Figures 1 and 2).
The following standard pharmacokinetics parameters were 
generated for individual ewes maximum observed ertapenem 
concentration (µg/mL); last observed ertapenem concentration 
(µg/mL, Clast); time to last observed ertapenem concentration 
(min; Tlast); area under the ertapenem concentration–time curve 
from time 0 to infinity ([µg/mL]×h; AUCinf); area under the er-
tapenem concentration–time curve from time 0 to last measure-
ment ([µg/mL]×h, AUClast); and ertapenem mean residence time 
(h; = AUMCinf/AUCinf; where AUMCinf is the area under the 
first-moment curve from time 0 to infinity [µg/mL×h2]). Area 
parameters (AUC, AUMC) were calculated by using the log-
linear trapezoidal rule. Ertapenem elimination half-life (h) was 
calculated as T1/2(λz) = ln (2)/λz, where λz is the slope of the 
terminal phase of the natural logarithm of concentrations com-
pared with time curve; ertapenem systemic clearance (mL/h/
kg) was dose/AUCinf; the volume of distribution (mL/kg) of er-
tapenem during the elimination phase was calculated as dose / 
AUCinf × λz; the volume of distribution (mL/kg) of ertapenem at 
steady-state was equal to systemic clearance × mean residence 
time. The extraction ratio (Ebody = systemic clearance / cardiac 
output) was calculated as reported previously,27 first calculated 
for each individual ewe and then combined for a mean value, 
with ewe cardiac output described27 as 180 × body weight (in 
kg)–0.19.
 Statistical analysis. Statistical analysis was completed using 
Prism 8.0.2 (GraphPad Software, La Jolla, CA). The respec-
tive data distributions for all pharmacokinetic parameters and 
group time point concentrations were assessed for normality 
by means of the Shapiro–Wilk test. Comparisons between the 
2 treatment groups were performed with unpaired t tests for 
parametric statistics and Mann–Whitney tests for nonparamet-
ric statistics as previously described.22 A P value less than 0.05 
was considered statistically significant.
Results
Ewe health. Ertapenem was well tolerated by all 8 ewes dur-
ing the study. No changes in appetite, behavior, or stool con-
sistency were noted. No adverse reactions were noted at the 
catheter sites.
Pharmacokinetics. No ewe had detectable ertapenem in 
plasma prior to commencement of the study. The average time 
course of ertapenem can be found in Figure 1. Geometric mean, 
median, minimum and maximum profiles after single-dose ad-
ministration are presented in Table 1. Among individuals there 
appears to be limited variation of time compared to concentra-
tion data for ertapenem in plasma. All ewes had no detectable 
concentrations of ertapenem in plasma after 6 h for the single-
dose study. No statistically significant differences were noted 
among time point concentrations when compared for the pres-
ence or absence of the immunomodulator or for single com-
pared to multiple dosing.
After initial dosing, ertapenem Cmax (mean ± 1 SD) was 232.6 ± 
50.8 µg/mL, AUClast was 144.0 ± 24.8 h×µg/mL, mean residence 
time was 0.7 ± 0.08 h, volume of distribution at steady state was 
78.3 ± 16.1 mL/kg, systemic clearance was 109.6 ± 17.9 mL/h/
kg and T1/2(λz) was 1.3 ± 0.6 h.
Ertapenem concentrations in plasma immediately prior to 
administration of the 5th dose were below the limit of detection. 
The geometric mean, median, minimum, and maximum plasma 
concentration profiles for each group after administration of the 
5th dose are presented in Table 2, and no detectable concentra-
tions were noted after 6 h in the multiple-dose study.
After multiple dosing (Figure 2), Cmax of ertapenem was calcu-
lated as 228.0 ± 52.8 µg/mL, AUClast was 138.7 ± 34.0 h×µg/mL, 
mean residence time was 0.7 ± 0.06 h, the volume of distribution 
at steady state was 84.5 ± 13.1 mL/kg, systemic clearance was 
116.3 ± 24.4 mL/h/kg, and T1/2(λz) was 1.1 ± 0.6 h.
No accumulation was noted, given that the majority of 8-h 
time points and all 10, 12, and 24 h timepoints demonstrated 
Figure 1. (A) Plasma concentration (mean ± 1 SD [error bars]) after 
a (A) single initial intravenous administration and (B) multiple-dose 
administration of ertapenem to sheep. The dashed line illustrates the 
limit of quantification for the assay (0.25 μg/mL).
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ertapenem concentrations below the limit of detection. The ex-
traction ratio for ertapenem in our ewes was 0.02 ± 0.004.
Statistical analysis. When parameters were compared with 
the values for the 1st and 5th administration of ertapenem, no 
significant differences were found for T1/2(λz) (P = 0.44), Cmax 
(P = 0.86), AUClast (P = 0.73), Vz (P = 0.65), systemic clearance 
(P = 0.88), AUMC (P = 0.97), mean residence time (P = 0.47), and 
Vss (P = 0.41). No significant differences in drug concentrations 
or pharmacokinetics between ewes were found regardless of the 
presence or absence of immunomodulator.
Discussion
Before using sheep as a model for human diseases with 
regard to carbapenem administration, it is important to under-
stand the pharmacokinetics of ertapenem in this species. With 
the increase of resistance in nosocomial infections in human 
hospitals requiring carbepenem therapy, additional animal 
investigations will need to be developed for translational stud-
ies. Sheep used in this study displayed ideal characteristics as 
subjects for a pharmacokinetic study. By commencement of 
this study, sheep were rapidly accustomed to halter restraint. 
Intravenous catheters maintained patency and allowed for ease 
of sample collection. Although ruminant urine pH differs from 
that of humans, it can be manipulated by dietary factors, such as 
the addition of ammonium chloride.14,26 This manipulation may 
be ideal for other investigations of ertapenem in experimentally 
infected sheep. The body weight of the sheep in this study (65.2 
± 7.7 kg) was similar to the weights of human patients in sev-
eral human pharmacokinetic studies (e.g., 76.2 ± 9.3 kg and 73 
kg).31,33 This similarity in body weights allow for translational 
dosing for sheep when ertapenem is dosed at 1 g/patient, as is 
common for humans.1,9,33 However, this similarity in total body 
mass does not account for differences in anatomy, such as the 
relatively larger size of the ruminant gastrointestinal system.
Our analysis revealed a short half-life for ertapenem, similar 
to what is described in human patients. The pharmacokinetic 
parameters and concentration at individual timepoints also 
demonstrated no differences after single or multiple adminis-
trations of ertapenem in sheep. This is noteworthy as our study 
sheep appear to have linear pharmacokinetics, again similar to 
humans. When ertapenem is administered to people, it can be 
given as either a 30-min or 5-min infusion, typically once daily.31 
The Cmax of our study in sheep (232.6 ± 50.8) is similar to that 
after a 5-min bolus in humans (195.9 ± 34.0).31
The volume of distribution at steady state for ertapenem—
after adjustment for bodyweight for our ewes—was 5.5 ± 0.14 L, 
which is descriptively similar to what is reported for human 
outpatients with complicated UTI (4.85 ± 1.8 L) but less than 
what is reported for healthy female human volunteers (7.5 ± 
0.9 L).13,33 In addition, the elimination half-life in our ewes was 
less than reported in either of those human studies. Although 
some of the pharmacokinetic parameters of ertapenem in sheep 
seemed lower than what is reported in human patients, it is 
important to note that specific disease status can alter ertape-
nem pharmacokinetics, such as sepsis can increase distribution 
volume and UTI can decrease this parameter. For example, in 
patients with severe sepsis treated with ertapenem, lower Cmax 
and AUC as well as larger volume of distribution were observed 
when compared with healthy human volunteers.2 A decreased 
volume of distribution has been noted in human outpatients 
with complicated UTI when compared with healthy volunteers, 
potentially a result of decreased clearance.33 Furthermore, age 
may also present an effect on the PK of ertapenem as in humans 
elderly people have higher AUC values when compared with 
younger persons.17
The extraction ratio of ertapenem in our current study sheep 
would be classified as low, because it is less than 0.05.27 This 
value is in the range of extraction by glomerular filtration (that 
is, 2% of cardiac output) and in agreement with previous de-
scriptions for humans.18 Although our results suggest some spe-
cies-specific differences in the pharmacokinetics of ertapenem in 
sheep and humans, it is important to note that analytical method 
sensitivity can have a profound effect on pharmacokinetics, as 
recently illustrated in the comparative pharmacokinetics of fen-
tanyl in large animal species.25 The limit of quantification of our 
assay was 0.25 µg/mL, and in the human literature limits of 
quantitation of 0.125 µg/mL have been reported.13 As noted for 
fentanyl concentrations in large animal species, when compar-
ing pharmacokinetic parameters it is important to consider ana-
lytical sensitivity as a lower limit of quantification can lead to 
the reporting of a longer elimination half-life. As such, it is pos-
sible that our analytical limits would yield decreased half-life 
and other parameters due to the higher limits of quantitation.
Adverse effects with ertapenem administration in people are 
primarily of concern for the nervous system. Several human 
Figure 2. Plasma concentration (mean ± 1 SD [error bars]) after (A) a 
single intravenous dose and (B) multiple intravenous doses of ertap-
enem in sheep treated without the immunomodulator (Ert) or with the 
immunomodulator (Ert + ZN). The dashed line illustrates the limit of 
quantification for the assay (0.25 μg/mL).
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patient undergoing peritoneal dialysis have developed seizures 
after the administration of ertapenem.23,32 In addition, seizures 
have been reported in elderly patients receiving ertapenem.1,29 
Among humans, stroke, low Hgb, and a low platelet count were 
identified as risk factors for seizures when administered ertape-
nem.10 Less common adverse effects, such as thrombocytopenia, 
have also been reported in human patients.5 Although safety 
evaluation was not a primary goal of this study, none of the 
sheep given ertapenem had overt seizure activity or neurologic 
disease, and none displayed the hematologic abnormalities as-
sociated with ertapenem in people.
Of note, organisms susceptible to ertapenem are typically 
inhibited by in vitro concentrations of less than or equal to 4 
µg/mL.18 The time above the minimal inhibitory concentration 
required for bacteriostasis for ertapenem in people is approxi-
mately 30% of the dosing interval.28 Given the shorter elimina-
tion half-life of ertapenem in sheep (1 h) when compared with 
human patients (approximately 3.5 h), future studies involving 
sheep models of infection may need to use an increased dosage 
(greater than the 1 g/ewe we used here) to maintain plasma 
concentrations above 4 µg/mL for 30% of the day with once-
daily dosing.
A limitation of our study was the relatively small sample size; 
however for veterinary pharmacokinetic studies, a sample size 
of 4 to 6 animals typically is sufficient to describe the pharma-
cokinetics of a test drug.3 Additional studies are required to ex-
plore the pharmacodynamics of ertapenem in sheep, as well 
as the potential synergistic effects of ertapenem and immuno-
modulators on bacteriuresis and resistance development.
In conclusion, our study established the pharmacokinetics 
of ertapenem in sheep used as a model for human biomedical 
research. No drug accumulation was reported after 5 d of 
dosing, which is consistent with the short elimination half-life 
of this antimicrobial in sheep. Likewise, the absence of notable 
difference between ertapenem clearance after single and mul-
tiple dosing is indicative of first-order elimination in sheep. 
This ovine model can be used to evaluate pharmacokinetics 
for therapeutic strategies for ertapenem use (varying drug dos-
ing schedules and combinations with other antimicrobials or 
immune modulators) in the context of UTI.
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